Human Longevity Inc. (HLI) is a company that utilizes genomic data and machine learning to enhance healthcare and improve the quality of life. With the largest database of genomic and phenotypic data, HLI is at the forefront of medical discoveries and innovations. The company offers various services, including the HLI Health Nucleus, which provides comprehensive health assessments using whole-genome sequencing, advanced imaging, and machine learning. HLIQ Whole Genome and HLIQ Oncology are also among their offerings. Founded in 2013 and based in San Diego, California, HLI is dedicated to revolutionizing the practice of medicine and empowering individuals to take control of their health.

Drugs associated with Human Longevity, Inc.

PSC-100

Target-

Mechanism

Cell replacements

Active Org.

Celularity, Inc. [+1]

Originator Org.

Celgene Corp. [+1]

Active Indication

Epidermolysis Bullosa [+1]

Inactive Indication

Hematologic Neoplasms [+2]

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

100 Clinical Results associated with Human Longevity, Inc.

0 Patents (Medical) associated with Human Longevity, Inc.

Literatures (Medical) associated with Human Longevity, Inc.

30 Apr 2019·Proceedings of the National Academy of Sciences of the United States of AmericaQ1 · CROSS-FIELD

Functional characterization of 3D protein structures informed by human genetic diversity

Q1 · CROSS-FIELD

Article

Author: Hicks, Michael ; Bartha, Istvan ; di Iulio, Julia ; Venter, J. Craig ; Telenti, Amalio

Sequence variation data of the human proteome can be used to analyze 3D protein structures to derive functional insights. We used genetic variant data from nearly 140,000 individuals to analyze 3D positional conservation in 4,715 proteins and 3,951 homology models using 860,292 missense and 465,886 synonymous variants. Sixty percent of protein structures harbor at least one intolerant 3D site as defined by significant depletion of observed over expected missense variation. Structural intolerance data correlated with deep mutational scanning functional readouts for PPARG, MAPK1/ERK2, UBE2I, SUMO1, PTEN, CALM1, CALM2, and TPK1 and with shallow mutagenesis data for 1,026 proteins. The 3D structural intolerance analysis revealed different features for ligand binding pockets and orthosteric and allosteric sites. Large-scale data on human genetic variation support a definition of functional 3D sites proteome-wide.

05 Feb 2019·Cell MetabolismQ1 · BIOLOGY

Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk

Q1 · BIOLOGY

Article

Author: Cirulli, Elizabeth T. ; Guo, Lining ; Leon Swisher, Christine ; Shah, Naisha ; Huang, Lei ; Napier, Lori A. ; Kirkness, Ewen F. ; Spector, Tim D. ; Caskey, C. Thomas ; Thorens, Bernard ; Venter, J. Craig ; Telenti, Amalio

Obesity is a heterogeneous phenotype that is crudely measured by body mass index (BMI). There is a need for a more precise yet portable method of phenotyping and categorizing risk in large numbers of people with obesity to advance clinical care and drug development. Here, we used non-targeted metabolomics and whole-genome sequencing to identify metabolic and genetic signatures of obesity. We find that obesity results in profound perturbation of the metabolome; nearly a third of the assayed metabolites associated with changes in BMI. A metabolome signature identifies the healthy obese and lean individuals with abnormal metabolomes-these groups differ in health outcomes and underlying genetic risk. Specifically, an abnormal metabolome associated with a 2- to 5-fold increase in cardiovascular events when comparing individuals who were matched for BMI but had opposing metabolome signatures. Because metabolome profiling identifies clinically meaningful heterogeneity in obesity, this approach could help select patients for clinical trials.

03 Jan 2019·American Journal of Human Genetics

Response to Whiffin et al.

Author: Shah, Naisha ; Claire Hou, Ying-Chen ; Yu, Hung-Chun ; Sainger, Rachana ; Caskey, C. Thomas ; Venter, J. Craig ; Telenti, Amalio

News (Medical) associated with Human Longevity, Inc.

01 Mar 2024

·www.businesswire.com

World Human Gene Sequencing Markets, Strategies, Trends, and Forecasts Report 2023-2024 and 2027 with Executive and Consultant Guides - 2023 to 2027 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Human Gene Sequencing Markets, Strategies & Trends - Forecasts by Application, by Technology, by Workflow, by Product, and by Country, with Executive and Consultant Guides - 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Will all newborns receive genetic testing at birth? What segments are growing fastest? Where are the opportunities now that sequencing has gone mainstream? The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out for five years. The report includes detailed breakouts for 14 countries and 5 regions. Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. Scope of the Report The Global Market for Human Genome Sequencing Global Market Overview by Country Global Market by Application - Overview Global Market by Technology - Overview Global Market by Workflow - Overview Global Market by Product - Overview Market Sizes by Application Hereditary Gene Sequencing Market NIPT Gene Sequencing Market Oncology Market Psychology Market WGES Gene Sequencing Market Pharmacogenomics Market DTC Gene Sequencing Market Research Gene Sequencing Market Other Application Market Market Sizes by Technology Sanger Sequencing Market NGS/2G Market 3G/Long Market Other Technology Market Market Sizes by Workflow Sequencing Market Sample Prep Market Analysis Market Market Sizes by Product Instruments Market Consumables Market Software & Services Market Vision of the Future of Human Gene Sequencing Key Topics Covered: 1 Market Guides 1.1 Human Gene Sequencing Markets - Strategic Situation Analysis & COVID Impact 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Gene Sequencing Definition In This Report 2.1.1 Gene Sequencing 2.1.2 Hereditary 2.1.3 Non Invasive Prenatal Testing 2.1.4 Oncology 2.1.5 Psychology 2.1.6 WGES 2.1.7 Pharmacogenomic 2.1.8 Direct to Consumer 2.1.9 Research 2.1.10 Other 2.2 The Genomics Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.4 Methodology 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 2.6 Chromosomes, Genes and Epigenetics 2.6.1 Chromosomes 2.6.2 Genes 2.6.3 Epigenetics 2.6.4 Genetic Testing vs. Gene Sequencing 2.6.5 Cost and Pricing Practice 3 Global Listing of Sequencer Installed Base - Location & Contacts 3.1 Notes to Installed Base Listing 3.2 Illumina Installed Base 4 Market Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 Human Gene Sequencing -Markets, Examples and Discussion 4.2.1 Inherited Disease - Not what it used to be 4.2.1.1 Clinical and Research Lines Blur 4.2.1.2 Genetic Counselling - Not so simple anymore 4.2.1.3 The Genetic Blizzard - Issues of Access and Payment 4.2.2 Newborn Screening - The Standard of Care 4.2.2.1 Newborn Screening - Do Parents Want to Know? 4.2.3 NIPT - We've Only Just Begun 4.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS 4.2.3.2 NIPT in the Future - Beyond Inherited Disease 4.2.4 Oncology - Understanding Two Worlds 4.2.4.1 The Tumor - A Sequence of Sequencing 4.2.4.2 The Tumor - Biopsy and Liquid Biopsy 4.2.4.3 The Human Genome - Predisposition and Prognosis 4.2.5 Pharmacogenomics 4.2.5.1 Sequencing Not the Only Player 4.2.5.2 New Roles for Old Drugs - A Research Bonanza? 4.2.6 Direct To Consumer - More Than Meets the Eye 4.2.6.1 DTC - How Many Segments? 4.3 Industry Structure 4.3.1 Hospital's Testing Share 4.3.2 The Rise of the Sequencing Lab 4.3.3 Sequencing as a Commodity 4.3.4 Informatics 4.3.5 Instrument Manufacturer Role 4.3.6 Healthcare Industry Impacts - Still Struggling 4.3.7 Can the Healthcare Industry Adapt? 4.3.8 Genetic Counselling as an Industry 4.3.9 Sequencing Adoption and Cannibalization 5 Market Trends 5.1 Factors Driving Growth 5.1.1 New Diagnoses 5.1.2 Wellness and Prevention 5.1.3 Fertility Technology 5.1.4 Cancer - Screening, Management and Monitoring 5.2 Factors Limiting Growth 5.2.1 Increased Competition Lowers Price 5.2.2 Lower Costs 5.2.3 Healthcare Cost Concerns Curtail Growth 5.2.4 Wellness has a downside 5.3 Sequencing Instrumentation 5.3.1 Instrumentation Tenacity 5.3.2 Declining Cost of Instruments Changes Industry Structure 5.3.3 Long Reads - Further Segmentation 5.3.4 Linked Reads 5.3.5 New Sequencing Technologies 6 Human Gene Sequencing Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 Natera Files Suit Against NeoGenomics 6.3 Genomics England to Sequence 100K Newborns 6.4 Novigenix Raises $14M for NGS based Liquid Biopsy 6.5 LetsGetChecked Launching New PGx Service 6.6 Qiagen, Neuron23 Partner for NGS Diagnostic 6.7 Harbinger Health Technology Focused On Oncogenesis 6.8 Delfi Diagnostics to Develop Early Detection Test 6.9 Dante Labs to Introduce WGS to Italian Healthcare System 6.10 Invitae Neurodevelopmental Disorders Testing Service 6.11 Thermo Fisher Obtains CE Mark for Ion Torrent Genexus 6.12 Myriad Genetics Launches Suite of Cancer Tests 6.13 Oncocyte and Thermo Fisher Strike Partnership Deal 6.14 Illumina Partners With Precision Medicine to Assess Liquid Biopsy 6.15 Sysmex Inostics Develops Ultra-Sensitive Liquid Biopsy 6.16 Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Testing 6.17 Strata Oncology Trial Supports NGS Assay 6.18 NYU Gets FDA Clearance for Sequencing Test 6.19 NeoGenomics to Acquire Inivata 6.20 OncoDNA, Institut Curie Partner on Liquid Biopsy Research 6.21 Cancer Heritability Gene Set Expanded 6.22 Whole-Genome Sequencing Could Replace Cytogenetics 6.23 Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays 6.24 Ancestry Shutters Health Offering 6.25 Genetron Health Targeting Early Cancer Detection 6.26 Pan-European Initiative to Build Tools for Sharing Genomic Data 6.27 UK Government Unveils New Genomic Healthcare Strategy 6.28 Foundation Medicine Liquid Biopsy Gets FDA Approval 6.29 American Heart Association Develops Genetic Testing Guidelines 6.30 Yourgene Health Gets CE Mark for Iona NIPT Test 6.31 NorthShore Looks to Expand Genomics Integration Into Primary Care 6.32 Germline Results From Tumor Sequencing Guides Precision Therapy 6.33 FDA Clears Cancer Genomic Profiling From Personal Genome Diagnostics 6.34 BillionToOne Closes $15M Series A Follow-on Round 6.35 Clinics to Integrate Genomics Into Primary Care Appendices United States Medicare System: January 2022 laboratory Fees Schedule The Whole Genome Sequence of SARS-CoV-2 Profiles of Key Companies 10x Genomics, Inc. 23andME Inc. Abbott Laboratories AccuraGen Inc. Adaptive Biotechnologies Admera Health, LLC Agilent/Dako Akonni Biosystems Amoy Diagnostics Co., Ltd. Ancestry.com LLC Anchor Dx Arc Bio Arrayit Corporation ARUP Laboratories Astrid Bio Baylor Miraca Genetics Laboratories Beckman Coulter Diagnostics Becton, Dickinson and Company BGI Genomics Co. Ltd Bioarray Genetics Biocept, Inc. Biodesix Inc. BioFluidica BioGenex Biolidics Ltd bioMerieux Diagnostics Bioneer Corporation Bio-Rad Laboratories, Inc. Bio-Techne C2i Genomics Caris Molecular Diagnostics CellMax Life Centogene Cepheid (Danaher) Circulogene Clinical Genomics Color Genomics Complete Genomics, Inc. - A BGI Company Dante Labs Datar Cancer Genetics Limited Diasorin S.p.A. Element Biosciences Epic Sciences Epigenomics AG Eurofins Scientific Excellerate Bioscience Fabric Genomics Freenome FUJIFILM Wako Diagnostics Fujirebio Fulgent Genetics GE Global Research Gene by Gene, Ltd. Genedrive GeneFirst Ltd. Genetron Holdings Genewiz Genomics England Genomics Personalized Health (GPH) GenomOncology Genzyme Corporation Grifols Guardant Health Guardiome HeiScreen Helix Helomics Hologic HTG Molecular Diagnostics Human Longevity, Inc. iCellate Illumina Incell Dx Inivata Integrated Diagnostics Invitae Corporation Invivoscribe Karius Letsgetchecked Lexagene Lunglife AI Inc Macrogen MDNA Life SCIENCES, Inc. MDx Health Medgenome Meridian Bioscience Mesa Biotech (Thermo Fisher) Mesa Laboratories, Inc. miR Scientific MNG Labs NantHealth, Inc. Natera Nebula Genomics 448 NeoGenomics New England Biolabs, Inc. NGeneBio Novogene Bioinformatics Technology Co., Ltd. Omega Bioservices Oncocyte OncoDNA OpGen ORIG3N, Inc. Origene Technologies Oxford Nanopore Technologies Panagene Perkin Elmer Personal Genome Diagnostics Personalis Precipio PrecisionMed Promega Protagen Diagnostics Qiagen QuantuMDx Regeneron Pharmaceuticals Roche Molecular Diagnostics Roswell Biotechnologies Seegene SeLux Diagnostics Sema4 Holdings Sequencing.com Siemens Healthineers simfo GmbH Singlera Genomics Inc. Singular Genomics SkylineDx Standard BioTools Sure Genomics, Inc. Sysmex Sysmex Inostics Tempus Labs, Inc. Thermo Fisher Scientific Inc. Ultima Genomics Variantyx Volition Vyant Bio For more information about this report visit https://www.researchandmarkets.com/r/nqo2do About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

26 Feb 2024

·www.prnewswire.com

Genetic Testing Markets - Global Market Analysis with Forecasts to 2027: Genetic Testing has Crossed the Chasm and is Now Growing in Every Area

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and Consultant Guides 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Unlimited growth potential? Genetic Testing has crossed the chasm and is now growing in every area. What are the opportunities? What are the pitfalls? The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life, and new problems for the industry. The report includes detailed breakouts for 14 countries and 5 regions. Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. This research makes you the expert in your organization. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered: 1 Market Guides 1.1 Genetic Testing - Strategic Situation Analysis & Company Rankings 1.1.1 Selected Genetic Testing Companies Revenue & Growth 1.1.2 Selected Companies Growth Chart 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Genetic Testing Definition in This Report 2.2 The Genomics Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.3.2 Newborn Screening 2.3.3 Non Invasive Pregnancy Testing 2.3.4 Predictive 2.3.5 Oncology 2.3.6 Direct to Consumer 2.3.7 Other Application 2.3.8 PCR 2.3.9 NGS 2.3.10 Cytogenetic 2.3.11 Other Technology 2.4 Methodology 2.4.1 Methodology 2.4.2 Sources 2.4.3 Authors 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 2.6 Chromosomes, Genes and Epigenetics 2.6.1 Chromosomes 2.6.2 Genes 2.6.3 Epigenetics 3 Market Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research Lab 3.1.2 Diagnostic Test Developer 3.1.3 Instrumentation Supplier 3.1.4 Chemical/Reagent Supplier 3.1.5 Pathology Supplier 3.1.6 Independent Clinical Laboratory 3.1.7 Public National/regional Laboratory 3.1.8 Hospital Laboratory 3.1.9 Physicians Office Lab (POLS) 3.1.10 Audit Body 3.1.11 Certification Body 3.2 Genetic Tests - Types, Examples and Discussion 3.2.1 Preimplantation Genetic Diagnosis - An Emerging Market 3.2.2 Prenatal Diagnosis - New Technologies Create Opportunity 3.2.3 Newborn Screening 3.2.4 Diagnostic Testing 3.2.5 Carrier Testing 3.2.6 Predictive and Presymptomatic Testing 3.2.7 Pharmacogenomics 3.2.8 Forensic Testing 3.2.9 Parental Testing 3.2.10 Ancestral Testing 3.3 Industry Structure 3.3.1 Hospital's Testing Share 3.3.2 Economies of Scale 3.3.3 Hospital vs. Central Lab 3.3.4 Physician Office Lab's 3.3.5 Physician's and POCT 4 Market Trends 4.1 Factors Driving Growth 4.1.1 Genetic Discoveries Creating New Diagnostic Markets 4.1.2 The Aging Effect 4.1.3 Pharmacogenomics Drives Further Growth 4.1.4 Oncology and Liquid Biopsy Enter New Era 4.1.5 Fertility Practice Growth drives market 4.1.6 Direct to Consumer begins to break out 4.2 Factors Limiting Growth 4.2.1 Increased Competition Lowers Price 4.2.2 Lower Costs 4.2.3 Testing usage analysis curtailing growth 4.2.4 Wellness has a downside 4.3 Instrumentation, Automation and Diagnostic Trends 4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point of Care 4.3.3 Instruments Key to Market Share 4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing 4.3.8 Whole Genome Sequencing, A Brave New World 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Genetic Testing Recent Developments 5.1 Recent Developments 5.1.1 Importance of This Section 5.1.2 How to Use This Section 5.2 Novitas Rescinds Coverage for Multiple Genetic Tests 5.3 PerkinElmer (now Revvity) Becomes Dx Life Science Firm 5.4 New POC Genotyping Tests Based on Electromagnetic Detection 5.5 GenoMe Dx Launching dPCR Cancer Test 5.6 mDetect To Trial Breast Cancer Liquid Biopsy 5.7 Genomics England, Aims to Sequence 100K Newborns 5.8 Juno Diagnostics NIPT With At-Home Sample Collection 5.9 Cardio Diagnostics Launches Genetic Cario Risk Test 5.10 Universal Genetic Testing in Breast Cancer Further Supported 5.11 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests 5.12 MyOme Lands Investment for WGS 5.13 Type 2 Diabetes GWAS Enables Risk Prediction 5.14 LetsGetChecked to Acquire Veritas Genetics 5.15 Guardant Health Plans New Comprehensive Assay 5.16 Tesis Labs Raises $20M 5.17 Sema4: Sema4 Elements 5.18 Clarified Precision Medicine Acquires Interpares Biomedicine 5.19 Genetic Technologies to Acquire DTC Genetic Test Provider EasyDNA 5.20 Illumina, Belgium Genetic Centers Partner on WGS-Based Dx 6 Profiles of Key Companies 6.1 10x Genomics, Inc. 6.2 23andME Inc. 6.3 Abbott Laboratories 6.4 Adaptive Biotechnologies 6.5 Admera Health, LLC 6.6 Agilent/Dako 6.7 Akonni Biosystems 6.8 Amoy Diagnostics Co., Ltd. 6.9 Ancestry.com LLC 6.10 Anchor Dx 6.11 Arc Bio 6.12 Arrayit Corporation 6.13 ARUP Laboratories 6.14 Aus Diagnostics 6.15 BaseClear 6.16 Baylor Miraca Genetics Laboratories 6.17 Beckman Coulter Diagnostics 6.18 Becton, Dickinson and Company 6.19 BGI Genomics Co. Ltd 6.20 Bioarray Genetics 6.21 Biocept, Inc. 6.22 Biodesix Inc. 6.23 BioFluidica 6.24 BioGenex 6.25 Biolidics Ltd 6.26 bioMerieux Diagnostics 6.27 Bioneer Corporation 6.28 Bio-Rad Laboratories, Inc 6.29 Bio-Techne 6.30 C2i Genomics 6.31 CareDx 6.32 Caris Molecular Diagnostics 6.33 CellMax Life 6.34 Centogene 6.35 Cepheid (Danaher) 6.36 Circulogene 6.37 Clinical Genomics 6.38 Color Genomics 6.39 Complete Genomics, Inc. - A BGI Company 6.40 CosmosID 6.41 Dante Labs. 6.42 Datar Cancer Genetics Limited 6.43 Diasorin S.p.A. 6.44 Element Biosciences 6.45 Element Biosciences 6.46 Epic Sciences 6.47 Epigenomics AG. 6.48 Eurofins Scientific 6.49 Excellerate Bioscience 6.50 Fabric Genomics 6.51 Freenome 6.52 Fujirebio 6.53 Fulgent Genetics 6.54 Gene by Gene, Ltd. 6.55 Genedrive 6.56 GeneFirst Ltd. 6.57 Genetron Holdings 6.58 Genomics England 6.59 Genomics Personalized Health (GPH) 6.60 GenomOncology 6.61 Genzyme Corporation 6.62 Grifols 6.63 Guardant Health 6.64 Guardiome 6.65 HeiScreen 6.66 Helix 6.67 Helix OpCo 6.68 Helomics 6.69 Hologic 6.70 HTG Molecular Diagnostics 6.71 Human Longevity, Inc. 6.72 iCellate 6.73 Illumina 6.74 Incell Dx 6.75 Inivata 6.76 Integrated Diagnostics 6.77 Invitae Corporation 7 Global Market Size 7.1 Global Market by Country 7.2 Global Market by Application 7.3 Global Market by Technology 7.4 Global Market by Product 7.5 Global Market by User 8 Market Sizes by Application 8.1 Newborn Testing Market 8.2 NIPT Market 8.3 Predictive Testing Market 8.4 Oncology Testing Market 8.5 DTC Testing Market 9 Global Genetic Testing Market by Technology 9.1 PCR Testing Market 9.2 NGS Market 9.3 Cytogenetic Testing Market 10 Global Genetic Testing Market by Product 10.1 Instruments Market 10.2 Reagents and Kits Market 10.3 Software Market 10.4 Services Market 11 Global Genetic Testing Market by User 11.1 Academic Market 11.2 Clinical Market 11.3 Pharmaceutical Market 11.4 Industrial and Other Market 12 The Future of Genetic Testing 13 Appendices 13.1 United States Medicare System: Laboratory Fees Schedule 13.2 The Most Used IVD Assays 13.3 The Highest Grossing Assays For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Acquisition

10 Jan 2024

·www.prnewswire.com

Global Cord Blood and Tissue Banking Industry Gains Traction Amidst Surging M&A Activity and Technological Advances

DUBLIN, Jan. 10, 2024 /PRNewswire/ -- The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering. Industry Analysis Unveils Consolidation Dynamics and Regional Market Expansion The global cord blood and tissue banking industry is undergoing a period of significant transformation characterized by robust merger and acquisition activities, technological innovation, and market expansion. A new research publication delves into the intricacies of this dynamic market, offering in-depth insights into current trends, future projections, and strategic developments through 2030. Amidst the spotlight on the healthcare sector for tailored and advanced therapeutic solutions, cord blood and tissue banking has emerged as a pivotal component. Cord blood, known for its potent hematopoietic stem cells, has a track record of over 40,000 transplants worldwide, heralding a new era in treatment options for a myriad of diseases. This comprehensive analysis not only highlights the milestones achieved in cord blood and tissue transplants but also sheds light on the storage capabilities of both public and private banks worldwide. Strategic Developments and Market Segmentation Public and private cord blood banks' cryopreservation units Global utilization of cord blood cells in regenerative medicine Emerging technologies enhancing public banks' financial sustainability Expansion services in the realm of cord blood banking Highlighting the geographical market expanse, the report underscores India's and China's dominant positions, collectively housing over a third of the world's population. Such demographics present vast opportunities for cord blood and tissue banking services. LifeCell International's commanding presence in India, managing over 320,000 stem cell units, exemplifies the regional market's potential. The U.S landscape has not been left behind in the wave of industry consolidation, with major players like CooperSurgical and Cryoholdco cementing their status through strategic acquisitions. With a focus on enhancing comprehensive cord blood banking services, the industry is witnessing expanded offerings that include reproductive services, genetic testing, and cell therapy product development. Furthermore, the report identifies the burgeoning market segments within the cord blood and tissue banking sphere, from storage market revenues and the therapeutic use of cord blood in transplantation medicine to the cutting-edge arena of regenerative medicine applications. Celebrating Scientific Progress and Market Evolution In a market ripe with scientific innovation, such as the groundbreaking FDA approval of Omisirge for recuperating cancer patients' white blood cells, the industry's potential is unmistakable. Moreover, the diverse application in clinical trials, with over 1,200 studies, illustrates the industry's pivotal role in advancing healthcare. The strategic report is an indispensable resource for stakeholders looking to navigate the complexities of the cord blood and tissue banking industry. It stands as a testament to the ongoing metamorphosis of this niche yet essential healthcare service, offering a horizon of opportunities for market participants and recipients alike. Advocating for informed decision-making and strategic positioning within the healthcare sector, this publication is an authoritative guide that equips entities with the knowledge to leverage the unfolding trends and optimize their operational footprint in the cord blood and tissue banking markets. As the industry continues to evolve, the insights from this report pave the way for informed dialogue, strategic planning, and competitive positioning within the global cord blood and tissue banking landscape. The report presents findings on the following topics: Number of cord blood and tissue units cryopreserved in public and private cord blood banks worldwide Number of hematopoietic stem cell transplants (HSCTs) performed globally using cord blood cells Utilization of cord blood cells in regenerative medicine clinical trials The decline of the utilization of cord blood cells in HSCT since 2005 Emerging technologies that will influence the financial sustainability of public cord blood banks The future scope for companion products derived from cord blood The changing landscape of the cord blood and tissue banking market Expansion and extension of services by cord blood banks Types of cord blood banks Economic model of public cord blood banks Cost analysis for public cord blood banks Economic model of private cord blood banks Cost analysis for private cord blood banks Profit margins for private cord blood banks Pricing for processing and storage in private banks Rate per cord blood unit in the U.S. and Europe Indications for the use of cord blood-derived HSCs within transplantation medicine Diseases targeted by cord blood-derived MSCs in regenerative medicine Cord blood processing technologies Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research Number and types of patents for cord blood, cord tissue, and placental products Transplantation data from different cord blood registries Companies Mentioned AllCells AlphaCord Americord Registry, Inc. Angiocrine Bioscience Anja Health Personalized Cord Blood Banking Anthony Nolan Baylx, Inc. Be The Match Biocell Center BioEden BioIntegrate, LLC Bloodworks Northwest California Umbilical Cord Collection Program Carolinas Cord Blood Bank (CCBB) Celaid Therapeutics Celebration Stem Cell Centre (CSCC) Cell Care Cellenkos, Inc. Cells4Life Group LLP CellSave Arabia Celularity, Inc. Center for International Blood and Marrow Transplant Research (CIBMTR) CHOC Blood Bank Cleveland Cord Blood Center ClinImmune Cell and Gene Therapy CooperSurgical Cord Blood Bank of Arkansas (CBBA) Cord Blood Center Group Cord Blood Registry (owned by CooperSurgical) Cord for Life CordLife Group, Ltd. CordVida Crioestaminal Cryo-Cell International, Inc. CryoCyte, LLC Cryoholdco Cryolife Cryopoint Cryoviva Biotech Pvt., Ltd. DentCell DKMS gGMBH Duke University School of Medicine European Society for Blood and Bone Marrow Transplantation (EBMT) Ever Supreme Bio Technology, Co., Ltd. ExCellThera FamiCord Group Fate Therapeutics, Inc. Future Health Gamida Cell GeneCell Global Cord Blood Corporation (GCBC) Glycostem Therapeutics Hawaii Cord Blood Bank HealthBaby HealthBanks Biotech Company Ltd. HealthBanksUSA HEMAFUND Hemogenyx Pharmaceuticals IMMUNIQUE Insception LifeBank JP McCarthy Cord Stem Cell Bank Kangstem Biotech, Co., Ltd. Life Line Stem Cell LifebankUSA LifeCell International Pvt. Ltd. LifeSouth Cord Blood Bank Magenta Therapeutics Maze Cord Blood MD Anderson Cord Blood Bank Medipost, Co., Ltd. Mesoblast, Ltd. MiracleCord, Inc. Mononuclear Therapeutics, Ltd. New England Cord Blood Bank, Inc. New York Blood Center OrganaBio PacifiCord PBKM FamiCord Plasticell Ltd. ReeLabs Pvt. Ltd. Restem, LLC San Diego Cord Blood Bank Saneron CCEL Therapeutics, Inc. Sanpower Group SmartCells SSM Cardinal Glennon Children's Medical Center Stem Cell Cryobank, Inc. Stembanc, Inc. StemCyte, Inc. Throne Biotechnologies, Inc. Transcell Biolife Upstate Cord Blood Bank VCANBIO Cell & Gene Engineering Corporation Versity, Inc. ViaCord Vita 34 AG Vitalant Clinical Services World Marrow Donor Association (WMDA) Worldwide Network for Blood & Marrow Transplantation (WBMT) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Acquisition

100 Deals associated with Human Longevity, Inc.

100 Translational Medicine associated with Human Longevity, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 03 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PSC-100	Muscular Atrophy More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis